Survival curves showing therapeutic efficacy of 20-2b in a disseminated Burkitt lymphoma (Daudi) xenograft model. Female C.B.17 SCID mice were administered Daudi cells intravenously on day 0. Treatments consisted of 20-2b (●), 734-2b (■), v-mab (○), PEGASYS (▾), or saline (X) given as a single subcutaneous dose. Days of treatment are indicated with arrows. Survival curves were analyzed using Prism software. (A) Early Daudi model. Groups of 10 mice were given a single dose of 0.7 pmol (solid line) or 0.07 pmol (dashed line) on day 1. (B) Advanced Daudi model. Groups of 10 mice were given a single dose of 0.7 pmol (solid line), 7 pmol (dashed line), or 70 pmol (gray line) on day 7.